Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Health Care Technology

SolventumSOLV

Health Care Technology · Saint Paul, Minnesota · In the S&P 500
Cheaper than peers
$81.33−2.67%After hours: $81.38 (+0.06%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 16.6% over 1 year
Solventum over 1 yearDaily close, $, to 30 Oct 2026
$70$90Nov2026MarMayJulSep$81.33NovMarJul$81.33
Source: Nasdaq daily closes
Market value$13.84B
Price to earnings9.9x
Forward P/E12.1x
Dividend yield–
Year to date+2.6%
One year+16.6%
Next earningsThu 5 Nov, after the close
SectorHealth Care
52-week range (closes)
$62.49$92.44

The latest on Solventum

Our stories first, then the headlines that could move it, newest first.

We haven't written about Solventum yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Solventum compares with other health care stocks. A description, not a recommendation.

Solventum and 5 health care technology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: weaker than mostValuation: cheaper than most

A weaker business than most health care companies, priced below most of them.

Solventum trades at 12.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: −0.9% vs +7.8%
  • Keeps less of each sale (gross margin): 54.7% vs 65.3%
  • More profitable (operating margin): 25.0% vs 13.3%
  • Turns less of its sales into cash: −1.4% vs 15.9%
SOLV trades at 12.1x forward earnings, below the sector medianForward p/e, Health Care Technology peers
SOLV12.1xNVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xLLY36.3xSector median 19.1xSOLV12.1xNVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 9.9x earnings, SOLV is cheaper than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x30xAverage 17.4x202520269.9x20xAverage 17.4x202520269.9x
Source: Nasdaq prices; SEC filings

Financials

From Solventum's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 2.2% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$1bn$2bnQ3 ’24Q1 ’25Q3 ’25$2.2bnQ2 ’26$0bn$1bn$2bnQ3 ’24Q1 ’25Q3 ’25$2.2bnQ2 ’26
Source: SEC filings
Growth sped up to +2.2% last quarterRevenue growth, year on year, %
−2%0%2%Q3 ’24Q1 ’25Q3 ’252.2%Q2 ’26−2%0%2%Q3 ’24Q1 ’25Q3 ’252.2%Q2 ’26
Source: SEC filings
Operating margin was 8.2% last quarterOperating income as a share of revenue, %
0%25%50%75%Q3 ’24Q1 ’25Q3 ’258.2%Q2 ’260%50%Q3 ’24Q1 ’25Q3 ’258.2%Q2 ’26
Source: SEC filings
Free cash flow was −$118 million over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
−$200m$0mQ3 ’24Q1 ’25Q3 ’25$144mQ2 ’26−$200m$0mQ3 ’24Q1 ’25Q3 ’25$144mQ2 ’26
Source: SEC filings
Last 12 monthsSOLVSector median
Revenue growth−0.9%+7.8%
Gross margin54.7%65.3%
Operating margin25.0%13.3%
Free cash flow margin−1.4%15.9%
Price to earnings9.9x30.2x

Similar companies

Health Care Technology, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
ABBVAbbVie$294.89+1.41%+29.1%$521B
MRKMerck$149.52+2.18%+42.0%$369B
UNHUnitedHealth$406.97−0.96%+23.3%$365B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B